These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34601021)

  • 21. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. M2 macrophages promote PD-L1 expression in triple-negative breast cancer via secreting CXCL1.
    Zhang L; Gu S; Wang L; Zhao L; Li T; Zhao X; Zhang L
    Pathol Res Pract; 2024 Aug; 260():155458. PubMed ID: 39003998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
    Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
    J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
    Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
    Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors.
    Dusenbery AC; Maniaci JL; Hillerson ND; Dill EA; Bullock TN; Mills AM
    Am J Surg Pathol; 2021 May; 45(5):701-707. PubMed ID: 33739790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
    Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
    Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer.
    Hu X; Li G; Li S; Wang Q; Wang Y; Zhang P; Yang T; Yang B; Yu L; Liu Z
    Biochem Biophys Res Commun; 2024 Jan; 694():149388. PubMed ID: 38150917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization.
    Kumar S; Tailor D; Dheeraj A; Li W; Stefan K; Lee JM; Nelson D; Keefe BF; Schedin P; Kummar S; Coussens LM; Malhotra SV
    Cell Rep Med; 2024 Sep; 5(9):101698. PubMed ID: 39181134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
    Zhao Y; Yu Y; Li X; Guo A
    J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
    Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y
    Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer.
    Wang Y; Chen Y; Ji DK; Huang Y; Huang W; Dong X; Yao D; Wang D
    J Nanobiotechnology; 2024 Aug; 22(1):461. PubMed ID: 39090622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
    Luo X; Wang H; Ji D
    Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
    Koh V; Chakrabarti J; Torvund M; Steele N; Hawkins JA; Ito Y; Wang J; Helmrath MA; Merchant JL; Ahmed SA; Shabbir A; Yan So JB; Yong WP; Zavros Y
    Cancer Lett; 2021 Oct; 518():59-71. PubMed ID: 34126195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
    Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
    Front Immunol; 2022; 13():830606. PubMed ID: 35935985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with PD-1 inhibition plus rapamycin and metformin enhances anti-tumor efficacy in triple negative breast cancer.
    Tan X; Li Y; Hou Z; Zhang M; Li L; Wei J
    Exp Cell Res; 2023 Aug; 429(1):113647. PubMed ID: 37225011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.